Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Geriatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Eur J Neurol. 2022 Sep;29(9):2639-2644. doi: 10.1111/ene.15417. Epub 2022 Jun 6.
Penetrance estimates of the leucine-rich repeat kinase 2 (LRRK2) variants for Parkinson disease (PD) vary widely. G2385R is one of the most common LRRK2 variants in Asian populations, and its penetrance is currently unknown. We aimed to estimate the penetrance of G2385R in the Chinese population.
The G2385R variant was tested by Sanger sequencing in 6386 participants older than 50 years, all from the community cohort established by Shanghai Ruijin Hospital in 2009-2011. G2385R carriers and matched noncarriers underwent a brief questionnaire survey (including sex, current age, PD diagnosis, and age at onset) and face-to-face PD assessment during 2020-2021. The penetrance of PD was estimated by the Kaplan-Meier method.
A total of 396 G2385R carriers and 415 noncarriers were included, after excluding those with a baseline diagnosis of PD or unwilling to participate. In G2385R carriers, the penetrance of PD was 1.64% at 70 years, 10.26% at 80 years, and 18.49% at 90 years, and reached 25.90% at 95 years. The penetrance of PD in G2385R carriers was higher than in noncarriers (p = 0.0071). In noncarriers, only 0%, 3.72%, and 9.66% developed parkinsonism by 70, 80, and 90 years of age. Among carriers and noncarriers, there were no statistically significant differences in penetrance comparisons between males and females, or between urban and rural.
The lifetime penetrance of LRRK2 G2385R in the Chinese population was 25.9%. The penetrance modifier of G2385R in our study was age-related. Further investigation of genetic and environmental modifiers affecting G2385R penetrance is warranted.
亮氨酸重复激酶 2(LRRK2)变异体的帕金森病(PD)外显率差异很大。G2385R 是亚洲人群中最常见的 LRRK2 变异体之一,但其外显率目前尚不清楚。我们旨在估计 G2385R 在中国人中的外显率。
2009-2011 年,我们对来自上海瑞金医院社区队列的 6386 名年龄大于 50 岁的参与者进行了 Sanger 测序检测 G2385R 变异。G2385R 携带者和匹配的非携带者在 2020-2021 年期间接受了简短的问卷调查(包括性别、当前年龄、PD 诊断和发病年龄)和面对面的 PD 评估。通过 Kaplan-Meier 法估计 PD 的外显率。
共纳入 396 名 G2385R 携带者和 415 名非携带者,排除了基线 PD 诊断或不愿参加的患者。在 G2385R 携带者中,70 岁时 PD 的外显率为 1.64%,80 岁时为 10.26%,90 岁时为 18.49%,95 岁时为 25.90%。G2385R 携带者的 PD 外显率高于非携带者(p=0.0071)。在非携带者中,70、80 和 90 岁时仅有 0%、3.72%和 9.66%发展为帕金森病。在携带者和非携带者中,男性和女性之间以及城乡之间的外显率无统计学差异。
LRRK2 G2385R 在中国人中的终身外显率为 25.9%。我们研究中 G2385R 的外显率修饰因子与年龄相关。需要进一步研究影响 G2385R 外显率的遗传和环境修饰因子。